ZPL 3893787

Drug Profile

ZPL 3893787

Alternative Names: PF-03893787; PF-3893787; ZPL-389; ZPL-3893787; ZPL-3893797

Latest Information Update: 04 Apr 2017

Price : $50

At a glance

  • Originator Pfizer
  • Developer Pfizer; Ziarco
  • Class Anti-inflammatories; Antiasthmatics; Pyrimidines; Pyrrolidines; Small molecules
  • Mechanism of Action Histamine H4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atopic dermatitis; Plaque psoriasis
  • Discontinued Asthma

Most Recent Events

  • 01 Dec 2016 Ziarco Pharma completes a phase II trial in Plaque psoriasis in United Kingdom, USA, Bulgaria and Poland (NCT02618616)
  • 13 Jun 2016 Final efficacy data from a phase IIb trial in Atopic dermatitis released by Ziarco Pharma
  • 16 May 2016 Top-line efficacy and adverse events data from a phase IIa trial in Atopic dermatitis released by Ziarco Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top